Under de kliniske undersøgelser forekom behandlingsafbrydelser, der skyldtes bivirkninger hos patienter med pulmonal arteriel hypertension, der modtog doser på 125 og 250 mg to gange dagligt med samme hyppighed (5, 8%) hos bosentan - og placebobehandlede patienter.
Treatment discontinuations due to adverse events, during the clinical trials in patients with pulmonary arterial hypertension, at doses of 125 and 250 mg twice daily, occurred with the same frequency (5.8%) in bosentan and placebo-treated patients.